This study is exploring a new treatment called **BMS-986504** for people with a type of pancreatic cancer called **MTAP-deleted PDAC**. There are three groups in the study. The first group will receive BMS-986504 along with chemotherapy before and after surgery. The other two groups will receive BMS-986504 with standard chemotherapy. **Chemotherapy** is medicine that helps stop cancer cells from growing. **PDAC** stands for pancreatic ductal adenocarcinoma, a common type of pancreatic cancer. To join the study, you must be at least 18 years old and have a specific genetic change called **MTAP deletion**, which can be checked through a simple test on your cancer tissue or blood. You also should not have other major health issues, including heart problems or other active cancers. **Key Points to Consider:** - The study will involve regular visits and follow-ups for treatment and tests. - Participants must agree to use effective birth control methods. - There may be risks, such as side effects from the treatment, but the study aims to find out if this new treatment can help control the cancer. For more information, it is important to discuss the details with a healthcare provider.